Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh'ok Aduke, just saw it on the otc listing and thought I would post it.
I don't know a thing about it.
appreciate it,
Mariner
SYNB is long history. Already got paid out. Waiting on the escrow. Someday, but that would be icing on the cake.
SYNB 3/9/2011 OTCBB SECURITY DELETIONS
Synbiotics Corporation Acquired by Pfizer Animal Health on 12/30/2010. Symbiotic's shareholders are entitled to receive approximately $0.2867385 per share.
Cash term excludes $0.019 per share to be held in escrow. **
http://www.otcbb.com/asp/dailylist_detail.asp?d=03/09/2011&mkt_ctg=ALL
My SNYB shares are in flux in my atrade acct??
Look at this news !!! I would love
to see Synbiotics-Shares goes to / over 1 Dollar.
Let´s see what the next days to come...........!!!
See this news :
http://www.bizjournals.com/kansascity/print-edition/2011/01/07/synbiotics-sale-to-pfizer-tops-20m.html
Synbiotics’ sale to Pfizer tops $20M mark
But fate of staff, HQ in Kansas City remains unclear
Kansas City Business Journal - by Aly Van Dyke , Staff Writer
Date: Friday, January 7, 2011, 5:00am CST - Last Modified: Thursday, January 6, 2011, 5:28pm CST
Pfizer Animal Health officially acquired Kansas City-based Synbiotics Corp. on Dec. 30.
The terms of the acquisition weren’t disclosed, but an industry source indicated that the purchase price was slightly more than $20 million.
Representatives from Synbiotics could not be reached for comment.
Synbiotics develops and manufactures immunodiagnostic tests for companion animals and livestock. It started in San Diego in 1982 and moved its headquarters to Kansas City in 2007.
In a Dec. 29 release, the companies said Synbiotics shareholders would receive 30.6 cents a share in cash, of which just less than 2 cents a share would be held ...
Read more: Synbiotics’ sale to Pfizer tops $20M mark | Kansas City Business Journal
Pfizer should pay to EPS, as an example
Share a Synbiotic-profit $ 0.05 / Year EPS is accepted, we would have a ratio of 6 at a price of $ 0.30!
Only an estimate - I do not know the exact numbers of course.
I think a ratio of 30 would aktzeptable, thus a rate of nearly 2 Dollars - my opinion.
What do you think ?????
4 $ /Share-would be a fair Price for SYNB !!!
0,30 ?? Is a scam. This should be a gift, that
i´m invested nearly 7 Years ago , vor 4 Dollars a Share ????
*grrrrr*
I hope Pfizer pays a lot more than 0,30 Cent - i
need 4 Dollars / Share !!!!
I hope Synbiotics Managemnet thinks on the old Shareholders of SYNB to !!!!
But it's only the sp movement that counts. ( :
Pretty nice dollar volume in here since the news!!
Nice payday for you here, Aduke.
Did you sell or are you expecting people to pay even more than what Pfizer is offering? ( ;
Wow....that makes no sense at all if anyone takes anytime at all to read the announcement......stock is worth .287 ps period. Anyone paying that or more is just throwing money away especially if the deal goes throw by the end of the week as stated.
Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector
Affirms Commitment to Providing Companion Animal and Livestock Veterinarians with Comprehensive Animal Health Solutions
MADISON, N.J., Dec. 29, 2010 /PRNewswire-FirstCall/ -- Pfizer Animal Health today announced an agreement to acquire Synbiotics Corporation (Pink Sheets: SYNB), a privately held, Kansas City-based leader in the development, manufacture and marketing of immunodiagnostic tests for companion and food production animals.
(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO )
Veterinary immunodiagnostics, a methodology using antigen-antibody reaction to detect viruses or bacteria in animals, is a sector growing an estimated 8% annually, twice the rate of the animal health industry as a whole. The global immunodiagnostics market is valued at $735 million, according to industry sources. Factors accelerating growth include increasing interest among companion animal owners in monitoring the health and maintaining wellness of their dogs, cats and horses. Likewise, livestock producers, striving to meet increasing worldwide demand for animal-derived food protein, are placing greater emphasis on immunodiagnostics to safeguard the health of livestock animals.
"Our acquisition of Synbiotics, with its best-in-class product portfolio, promising research and development pipeline, and manufacturing capability, will bring Pfizer Animal Health closer to its goal of becoming a comprehensive solutions provider to the animal health industry," said Juan Ramon Alaix, president, Pfizer Animal Health. "By integrating animal health diagnostics with our innovative portfolio of vaccines and medicines, we can do more to help veterinarians deliver optimal care for livestock and companion animals and provide the right medicine to the right animal at the right time."
According to Mr. Alaix, the acquisition will not only allow Pfizer Animal Health to enhance its offerings to veterinarians at point of care in the clinic and on the farm, but also to expand into products for diagnostic reference laboratories and reproductive services for canine breeders.
"We look forward to continuing to serve existing Synbiotics customers as well as serving new customers with Synbiotics' portfolio of proven and effective diagnostics solutions," Mr. Alaix said.
"Pfizer Animal Health is the ideal partner for Synbiotics," said Paul Hays, Chief Executive Officer of Synbiotics Corporation. "Pfizer Animal Health's global reach, commercial operations, and expertise in regulatory and marketing functions will expand customer access to such leading products as WITNESS® and ASSURE® for companion animals, the SERELISA® franchise for livestock animals, and PROFLOK for poultry into new markets -- especially in emerging markets. Marrying Synbiotics' R&D expertise in diagnostics with the strength of Pfizer veterinary R&D also is expected to help accelerate our diagnostic development program."
According to Hays, Synbiotics estimates that its common shareholders will be entitled to receive up to approximately $0.306 per share in cash in connection with the acquisition, of which approximately $0.019 per share will be held in escrow as a fund against which Pfizer may make claims for losses arising from any breaches of Synbiotics' representations, warranties, covenants and agreements and similar customary matters. The acquisition is expected to close later this week.
With its agreement to acquire Synbiotics, Pfizer Animal Health is affirming its commitment to help companion animals and horses live healthier longer lives and to help assure a safe food supply from healthy cattle, poultry, pigs and fish worldwide using sustainable production practices. Pfizer Animal Health's entry into veterinary diagnostics follows a series of moves in 2010 that position the business as the partner of choice to the animal health industry. These include:
Completing a licensing and development agreement with Epitopix to expand access to the first conditionally U.S. Department of Agriculture approved vaccines for E. coli and for Salmonella Newport in beef and dairy cattle.
Expansion into the rapidly growing aquaculture segment with the acquisition of Microtek International.
Entry into animal health generic medicines with the acquisition of Vetnex in India.
About Synbiotics Corporation
Synbiotics is a leading developer and manufacturer of veterinary diagnostics and services for veterinary practices, livestock and poultry producers, reference laboratories and animal breeders worldwide. New product R&D is centered at the Synbiotics headquarters in Kansas City, Missouri and also performed in manufacturing locations in Lyon, France and in San Diego, California, and through R&D collaborations with the University of Maryland and Kansas State University. Synbiotics' facilities are permitted by the United States Department of Agriculture (USDA) and are ISO 9001 certified. For more information, visit www.Synbiotics.com.
Pfizer Inc.: Working together for a healthier world™
At Pfizer (NYSE: PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.
DISCLOSURE NOTICE: The information contained in this release is as of December 29, 2010. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about an agreement by Pfizer to acquire Synbiotics Corporation, including the anticipated price per share, and about Synbiotics' product portfolio and research and development pipeline, including the potential benefits thereof. Such information involves substantial risks and uncertainties including, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development activities; and competitive developments.
A further list and description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
SOURCE Pfizer Inc.
Back to top
RELATED LINKS
http://www.pfizer.com
http://www.prnewswire.com/news-releases/pfizer-animal-health-to-acquire-synbiotics-corporation-entering-diagnostics-sector-112607529.html
looking for info on payout date of the ~.287 once this closes, has anyone seen any? Also, how long is the .019 held in reserve until it (or whatever is left) is paid out as well?
he who laughs last....
That's for sure! hahahahhahahahaha ...
he who laughs last... ?? is that some kind of investor saying sentence or something?
he who laughs last....
What will Pfizer do with SYNB, that name attached to this Stock will bring in Big $$$$!!
LOL, I was kidding. You can't play the pennies if you don't have sense of humor.
How can SYNB go to "dollarland" when Pfizer will only pay .306?
Even though the buyout is .306 pps, I would like to see .50+ within the next few days!!! This had zero attention prior to this news, momo should keep it in play for a while based on todays news!
SYNB....According to Hays, Synbiotics estimates that its common shareholders will be entitled to receive up to approximately $0.306 per share in cash in connection with the acquisition, of which approximately $0.019 per share will be held in escrow as a fund against which Pfizer may make claims for losses arising from any breaches of Synbiotics ' representations, warranties, covenants and agreements and similar customary matters. The acquisition is expected to close later this week.
See you all in 100 dollar land!!!!!!!!!! LOL
Huuuuggggeeeeee!!!!!!
KAAABBBBBBBBBBBBOOOOOOOOMMMMMMMMMMMMMMMMMMM!!!
SYNB - Product News: http://www.synbiotics.com/NewsAndEvents/ProductNews/2010.html
October 28, 2010 - Synbiotics Partners with Merial to Provide MERIAL Flu-Kit for Identification of Swine Influenza
The Synbiotics Flu DETECT™ SWINE diagnostic kit is included in the MERIAL Flu-Kit which has just been introduced by Merial for use by veterinarians. Flu DETECT™ Swine Influenza Virus Type A Antigen Test Kit is an in-vitro, Rapid Immuno Migration (RIM™) test designed to aid in the qualitative detection of Swine Influenza Type A virus in nasal samples from pigs.
Details of the MERIAL Flu-KIT are outlined in the following Merial press release…
“After GRIPOVAC®3, MERIAL introduces the Merial Flu-Kit to assist the identification of swine influenza in the field.
After the recent launch in all European countries of GRIPOVAC®3, Merial is now introducing the first-ever MERIAL Flu-Kit to confirm the presence of swine influenza virus (SIV) in the field.
GRIPOVAC®3 is a new swine influenza vaccine including three subtypes of the Swine Influenza Virus (H1N2, H1N1 and H3N2); these strains are updated strains and respond to field requirements of European countries where the strains are circulating.
The MERIAL Flu-Kit is a diagnosis tool-box intended for use by Veterinarians to help them identify the presence of SIV by in-the-field diagnosis. The kit includes all materials necessary to perform on-the-farm diagnosis: a swine flu clinical symptom reminder card, a thermometer, a Synbiotics Flu Detect™ swine diagnostic kit, nasal swabs and instructions for use.
The Synbiotics Flu Detect™ swine diagnostic kit enables quite simply to know if SIV is present or not in a fever-affected pig; it does not identify which specific strain is involved - this can of course only be performed by PCR and viral isolation from the nasal swab in local labs.
For further information regarding the obtention and use of the MERIAL Flu-Kit in your country, please contact your Merial representative.
Gripovac®3, developed with IDT-BIOLOGIKA, was granted market authorisation on 14th January 2010 by the European Commission and will be distributed by Merial in all European countries except Germany (IDT) in 25 or 50-dose bottles according to the country.
For further information on Swine Influenza please consult: www.aboutswineinfluenza.com (available soon).”
Merial Flu-Kit
Press Contacts
Thaïs Vila DVM
Swine Technical Director
EMEA Business Operations
Thais.vila@merial.com
Amanda Evans BA
Manager, Business Operations Communications
EMEA
Amanda.evans@merial.com
For additional details about Merial, please go to www.merial.com.
Synbiotics has corporate headquarters in Kansas City, Missouri with ISO certified manufacturing facilities in Lyon, France and San Diego, California.
For years, Synbiotics has been a leader in the detection of Avian Influenza Virus and this technology has facilitated the development of Flu DETECT™ SWINE as well as Flu DETECT™ EQUINE. Interested individuals may learn more about Synbiotics at www.synbiotics.com.
http://www.synbiotics.com/NewsAndEvents/ProductNews/2010.html
SYNB Events - Busy year ahead:
http://www.synbiotics.com/NewsAndEvents/Tradeshows/Events.html
Even in these times of corporate downsizing, Synbiotics is recruiting:
Molloy Recruited as Vice President, Sales and Marketing and Synbiotics Officer
Synbiotics Corporation is pleased to announce that Mr. Ronan Molloy has joined the
company as Vice President, Sales & Marketing and will serve the company as an
officer and member of its Executive Management Committee. Synbiotics President
and CEO, Mr. Paul Hays stated, “Ronan has a proven track record in growing
businesses and will play a key leadership role in Synbiotics”. Molloy will lead and
direct the Synbiotics Area Sales Managers, Marketing Services and Strategic
Marketing.
Molloy comes to Synbiotics with an extensive educational and commercial
background. Molloy received a Bachelors degree in Economics from the University of
Kansas and a Juris Doctor degree from the University of Missouri-Kansas City School
of Law. His track record in growing businesses is exemplified by his 10 years at Primus
Corporation where, as their lead sales producer, he ascended from Regional Sales
Manager to Vice President of International Sales & Marketing. Most recently, Ronan
has been principle of RPM Consultancy LLC a Life Science Consulting firm specializing in
International Sales Expansion, Corporate Strategy and M&A.
Synbiotics Corporation is a leading developer, manufacturer and marketer of
veterinary diagnostics and services for veterinary practices, livestock and poultry
producers, reference laboratories and animal breeders world-wide. We are the
leader in animal diagnostics of zoonotic pathogens. Synbiotics manufactures at two
sites with one facility in San Diego, California and one operating out of Lyon, France
providing innovative, quality products and services for the health and well-being of
animals. Both facilities are permitted by the United States Department of Agriculture
(USDA) and are ISO 9001 certified.
http://www.synbiotics.com/NewsAndEvents/CorporateNews/2010.html
Synbiotics Produces New Ruminant Kit for the Detection of Paratuberculosis
Synbiotics Europe announces the release of a new ruminant kit for sale from the Lyon manufacturing facility. The newest addition to our broad ruminant product line is SERELISA® M. ParaTB Ab Mono Indirect kit. The ELISA detects Mycobacterium Avium Sub. paratuberculosis antibodies for the diagnosis of Paratuberculosis (Johne's disease) in ruminants. It can be used in individual serum or plasma from cattle, as well as individual sheep, goat or milk samples.
For use within the United States, customers are encouraged to contact Synbiotics regarding import availability.
Synbiotics manufactures products for virtually every major ruminant disease. These diagnostic kits feature two major ELISA lines, SERELISA® and LACTELISA®, for use with primarily serum or milk samples, respectively. The leader in animal diagnostics for zoonotic pathogens, Synbiotics Corporation, markets veterinary diagnostics and services for veterinary practices, livestock and poultry producers, reference laboratories and animal breeders world-wide. Headquartered in Kansas City, Missouri, Synbiotics develops and manufactures its products at production facilities in San Diego, California and Lyon, France.
http://www.synbiotics.com/NewsAndEvents/ProductNews/2010.html
Allen D. Leman Swine Conference
September 18 - 21, 2010
RiverCentre Conference
St. Paul, Minnesota
http://www.synbiotics.com/NewsAndEvents/Tradeshows/Events.html
Woodard Promoted to Vice President, Production and Synbiotics Officer - July 16, 2010
The Synbiotics Board of Directors has unanimously agreed to promote Michael Woodard to the position of Vice President, Production as well as to appoint him an officer of Synbiotics Corporation. Synbiotics President and CEO, Mr. Paul Hays stated, “Mike has demonstrated strong leadership, planning and management skills in his current position and the Board of Directors is confident in his ability to continue to contribute to the company’s growth and financial success.”
Woodard joined Synbiotics in 2005 and quickly rose to Executive Director of Operations in the San Diego facility. His tenure has included continuous improvement of manufacturing and distribution. Earning a B.A. in Operations Management from California State University Fullerton in 1992, Woodard gained nineteen years of valuable experience in the electronics industry including manufacturing management positions with Diceon Electronics and Sanmina-SCI. Mr. Woodard holds CPIM and CSCP certifications through APICS and a Six Sigma Black Belt certification through ABI.
Woodard is respected by his colleagues throughout the global company. Synbiotics manufactures at two sites with one facility in San Diego, California and one operating out of Lyon, France providing innovative, quality products and services for the health and well-being of animals. Both facilities are permitted by the United States Department of Agriculture (USDA) and are ISO 9001:2000 certified.
At 5 Dollar´s i think about it,
to sell my shares, after many
Years of holding it.......!! )
How wants to buy my SYNB-Shares for 5 Dollar´s ?
SYNB Faire Value at 3-4 Dollars ???
It´s is possible that SYNB ist going back on "Stock-Market"
with it Shares in the next time ? ---> To OTCBB ??
It´s look like, then the old Shares traded on Stock-Market
after many Years , but they going Privat many Years ago.
What do you think ??
SYNB - Updated 2010 Events: http://www.synbiotics.com/NewsAndEvents/Tradeshows/Events.html
Western Veterinary Conference
February 14 - 18, 2010
Mandalay Bay Convention Center
Las Vegas, Nevada
ATTEND ONLY
www.aasv.orgAmerican Association of Swine Veterinarians
March 8 - 9, 2010
Hilton Omaha Hotel & Qwest Center
Omaha, Nebraska
Tech Table
www.midwestpoultry.comMidwest Poultry Federation
March 16 - 18, 2010
St. Paul RiverCentre
St. Paul, Minnesota
BOOTH #355
Size: 10x10
www.cevs.ucdavis.eduWestern Poultry Disease Conference
April 18 - 21, 2010
Fairmont Hotel
Vancouver, British Columbia, Canada
ATTEND ONLY
www.avda.netAmerican Veterinary Distributors Association (AVDA)
April 18 - 20, 2010
Silverado Resort
Napa, California
ATTEND ONLY
www.ipvs2010.comInternational Pig Veterinary Society
July 18 - 21, 2010
Vancouver Convention Centre
Vancouver, BC, Canada
www.avma.orgAmerican Veterinary Medical Association (AVMA)
July 11 - 14, 2010
Atlanta, Geogia
ATTEND ONLY
www.therio.orgSociety for Theriogenology Annual Conference & Symposium
August 31 - September 5, 2010
Grand Hyatt Seattle
Seattle, Washington
BOOTH
www.cvccentral.comCentral Veterinary Conference (CVC)
August 28 - 31, 2010
Kansas City, Missouri
ATTEND ONLY
www.cvm.umn.eduAllen D. Leman Swine Conference
September 18 - 21, 2010
RiverCentre Conference
St. Paul, Minnesota
www.aavld.orgAmerican Association of Veterinary Laboratory Diagnostic (AAVLD)
United States Animal Health Association (USAHA)
October 14 - 21, 2010
Minneapolis Hilton
Minneapolis, Minnesota
www.aaep.orgAmerican Association of Equine Practicioners (AAEP)
December 5 - 9, 2010
Mandalay Bay Hotel & Casino
Las Vegas, Nevada
Synbiotics Launches Ecommerce Online Ordering Site
http://www.synbiotics.com/index.html
SYNB Corporate News - first in a long time:
http://www.synbiotics.com/NewsAndEvents/CorporateNews/2010.html
Synbiotics Develops New, User Friendly, Global Website
Kansas City, Missouri - On December 24, 2009, Synbiotics launched its new global website at www.Synbiotics.com. The site provides a complete resource for all Synbiotics products manufactured in the US and France. In addition, the ease and efficiency of navigation have been significantly improved; these qualities are in line with Synbiotics’ customer centric mission. The website was developed under the initiative of Synbiotics Vice President of Sales and Marketing, Mr. Kevin Hayes. Hayes stated, “The new website demonstrates our commitment to global leadership and our mission to be the preferred diagnostic resource in the animal health industry.”
The enhanced website also features an entire Reproduction Services section providing educational information and resources to our customers. Synbiotics stores the largest collection of canine frozen semen in the world and offers assistance and services to veterinarians and breeders across the globe.
Synbiotics Corporation is a leading developer, manufacturer and marketer of veterinary diagnostics and services for veterinary practices, reference laboratories and animal breeders world-wide. Our core competencies include immunology, immunodiagnostics and reproduction. Synbiotics manufactures at two sites: San Diego, California and Lyon, France. Both facilities are permitted by the United States Department of Agriculture (USDA) and are ISO 9001:2000 certified.
Synbiotics’ website can be accessed at www.Synbiotics.com.
SYNB 2010 Events
http://www.synbiotics.com/NewsAndEvents/Tradeshows/Events.html
www.tnavc.org
The North American Veterinary Conference
January 16 - 20, 2010
Gaylord Palms Hotel
Orlando, Florida
BOOTH #1125/1127
Size: 20x20
www.poultryegg.orgInternational Poultry Exposition
January 27 - 29, 2010
Georgia World Congress Center
Atlanta, Georgia
BOOTH #5431
Size: 20x20
www.wvc.org
Western Veterinary Conference
February 14 - 18, 2010
Mandalay Bay Convention Center
Las Vegas, Nevada
ATTEND ONLY
www.midwestpoultry.com
Midwest Poultry Federation
March 16 - 18, 2010
St. Paul RiverCentre
St. Paul, Minnesota
BOOTH #355
Size: 10x10
www.cevs.ucdavis.edu
Western Poultry Disease Conference
April 18 - 21, 2010
Fairmont Hotel
Vancouver, British Columbia, Canada
ATTEND ONLY
www.avda.net
American Veterinary Distributors Association (AVDA)
April 18 - 20, 2010
Silverado Resort
Napa, California
ATTEND ONLY
www.aavld.org
American Association of Veterinary Laboratory Diagnostic (AAVLD)
United States Animal Health Association (USAHA)
October 14 - 21, 2010
Minneapolis Hilton
Minneapolis, Minnesota
Copyright ©1995-2009 Synbiotics Corporation. All Rights Reserved. Privacy Policy | Terms
Site Design & Maintenance by Nadler & Associates, Inc.
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
56
|
Created
|
03/04/08
|
Type
|
Free
|
Moderators |
Filed Form 15-12G - November 03, 2005 - http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=3992159
Continues business operations.
Contact Information
Synbiotics Corp.
12200 NW Ambassador Drive
Suite 101
Kansas City, MO 64163
Phone: 800-228-4305
Fax: 816-464-3521
E-mail: info@synbiotics.com
Company website: http://www.synbiotics.com/index.html
http://www.otcmarkets.com/stock/SYNB/company-info
Business Description
Synbiotics Corporation is a leading developer, manufacturer and marketer of veterinary diagnostics and services for veterinary practices, reference laboratories and animal breeders world-wide. Our core competencies include immunology, immunodiagnostics and reproduction. Application of these allows Synbiotics to serve mankind through products and services that contribute to: the production of a healthy and abundant protein food supply and to a long and rich bond with our companion animals.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |